Back to Agenda
Data and Methods for Signal Detection: Where are we Today and What is the Current State of the Art
Session Chair(s)
Andrew Bate, PHD, MA
Vice President, Head of Safety Innovation and Analytics
GSK, United Kingdom
Signal detection remains central to Pharmacovigilance activities. Better access and use of data, ever improving methods to maximise the utility of data, and better processes and governance to optimise signal detection activities are key focus areas as we continuously strive to do ever earlier and more effective safety signal detection. This session will discuss the current status of signal detection from all these aspects as well as how we anticipate the field evolving moving forwards.
Learning Objective : Demonstrate and discuss how Generative AI can facilitate the future approach in augmenting PV systems in a trusted, compliant, and transparent manner; Summarize the opportunities and challenges with such an approach.
Speaker(s)
Industry Perspective
Mariette Boerstoel-Streefland, MD, MBA, MS
Bristol Myers Squibb, United States
Senior Vice President, Patient Safety Officer
Panelist
Jeremy Jokinen, PHD, MS
Argenx, United States
Vice President and Head Global Patient Safety
Phil Tregunno
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director - Patient Safety Monitoring
Have an account?